ESTÁ A SAIR DO WEBSITE DA LUNDBECK.PT

Está a sair do website da Lundbeck.pt e a aceder ao website corporativo no qual a nossa Política de Privacidade não se aplica. As suas interações no website de destino serão da sua inteira responsabilidade.

Prosseguir

Cancelar

Publicações

Publicações em coautoria com cientistas da Lundbeck

O nosso compromisso com a ciência está refletido no histórico das nossas publicações. Aqui pode encontrar as publicações mais recentes em coautoria com os cientistas da Lundbeck.

Article  Product Authors Publication links Year Journal
6-Month Use of Droxidopa for Neurogenic Orthostatic Hypotension
Droxidopa Francois C, Shibao CA, Biaggioni I, Duhig AM, McLeod K, Ogbonnaya A, Quillen A, Cannon J, Padilla C, Kymes S, Yue B Read publication 2019 Movement Disorders Clinical Practice
A long-term, open-label study to evaluate the safety and tolerability of brexpiprazole as adjunctive therapy in adults with major depressive disorder Brexpiprazole  Hobart M, Zhang P, Brewer C, Hefting N Read publication 2019 Journal of Clinical Psychopharmacology
A new principal stratum estimand investigating the treatment effect in patients who would comply, if treated with a specific treatment Brexpiprazole  Groes Larsen K, Krog Josiassen M Read publication 2019 Statistics in Biopharmaceutical Research
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of vortioxetine in Japanese patients with major depressive disorder Vortioxetine Inoue T, Sasai K, Kitagawa T, Nishimura A, Inada I Read publication 2019 Psychiatry and Clinical Neurosciences
A Systematic Literature Review Identifying Associations Between Outcomes and Quality of Life (QoL) or Health Care Resource Utilisation (HCRU) in Schizophrenia Lu AF35700 Germain N, Weatherall J, Kymes S, Löf E, Jakubowska A, François C Read publication 2019 Journal of Medical Economics
Adapting the goal attainment approach for major depressive disorder Vortioxetine McCue M, Parikh S, Mucha L, Sarkey S, Cao C, Eramo A, Opler M, Lind B, Francois C Read publication 2019 Neurology and Therapy
Agitation in patients with dementia: a systematic review of epidemiology and association with severity and course Brexpiprazole  Anatchkova M, Brooks A, Swett L, Hartry A, Duffy RA, Baker RA, Hammer-Helmich L, Sanon Aigbogun M Read publication 2019 International Psychogeriatrics 
Anti-tau antibody-mediated clearance in mouse microglia cultures requires Fcγ-receptor interaction and functional lysosomes AF87908 Tau Andersson CR, Falsig J, Stavenhagen JB, Christensen S, Kartberg F, Rosenqvist N, Finsen B, Pedersen JT Read publication 2019 Scientific Reports
Assessment of current clinical practices for major depression in Japan using a web-based questionnaire Vortioxetine Hori H, Kentaro Y Read publication 2019 Neuropsychiatric Disease and Treatment
Brexpiprazole has a low risk of dopamine D2 receptor sensitization and inhibits rebound phenomena related to D2 and serotonin 5-HT2A receptors in rats Brexpiprazole  Amada N, Akazawa H, Ohgi Y, Maeda K, Sugino H Kurahashi N, Kikuchi T, Futamura T Read publication 2019 Neuropsychopharmacology Reports
Burden of Care for Treatment-Resistant Schizophrenia: A Quantitative Caregiver Survey of Experiences, Attitudes and Perceptions Lu AF35700 Velligan D, Brain C, Bouérat Duvold L, Agid O, Read publication 2019 Frontiers in Psychiatry
Canadian economic impact of improved workplace productivity in patients with major depressive disorder treated with vortioxetine Vortioxetine

Lachaine J, Beauchemin C, Bibeau J,

Patenaude J, Chokka P, Proulx J, Bougie J 

Read publication 2019 CNS Spectrums
Characteristics, Burden and Pharmacotherapy of Treatment-Resistant Schizophrenia: Results From a Survey of 204 US Psychiatrists Lu AF35700 Correll CU, Brevig T, Brain C Read publication 2019 BMC Psychiatry
Clinical Guidance on the Identification and Management of Treatment-Resistant Schizophrenia Lu AF35700 Agid O, Baldwin M, Correll C, Howes O, Kane J, Lindenmayer JP, Marder S, Olfson M, Potkin S Read publication 2019 Journal of Clinical Psychiatry
Clinical implications of directly switching antidepressants in well-treated depressed patients with treatment-emergent sexual dysfunction: a comparison between vortioxetine and escitalopram Vortioxetine Jacobsen PL, Zhong W, Nomikos GG, Affinito J, Cutler AJ, Clayton  Read publication 2019 CNS Spectrums
Cognitive symptoms in major depressive disorder: Associations with clinical and functional outcomes in a 6-month, non-interventional, prospective study in China Vortioxetine Wang G, Si T-M, Li L-J, Fang Y-R, Wang C-X, Wang L-N, Tan K H X, Ettrup A; Eriksen F H-L, Luo S, Ge L Read publication 2019 Neuropsychiatric Disease and Treatment
Comparisons of Global Tests on Intersection Hypotheses and Their Application in Matched Parallel Gatekeeping Procedures Brexpiprazole  Ouyang J, Zhang P, Carroll KJ, Lee J, Koch G Read publication 2019 Journal of Biopharmaceutical Statistics
Creation and validation of a linear index to measure the health state of patients with depression in automated healthcare databases Vortioxetine Touya M, Lamy FX, Tanaescu A, Saragoussi D, Francois C, Wade A, Llorca PM, Lancon C, Falissard B Read publication 2019 Journal of Market Access & Health Policy
Development of a Classifier to Identify Patients with Probable Lennox–Gastaut Syndrome in Health Insurance Claims Databases Via Random Forest Methodology Clobazam Vekeman F, Piña-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Saurer TB, Montouris GD, Isojarvi J Read publication 2019 Current Medical Research & Opinion
Differences in perceptions of major depressive disorder symptoms and treatment priorities between patients and health care providers across the acute, post-acute, and remission phases of depression Vortioxetine Baune B, Christensen MC Read publication 2019 Frontiers in Psychiatry
Drug-Drug Interactions With Concomitant Clobazam and Cannabidiol Usage in Refractory Seizures Clobazam Tolbert D, Klein P, Gidal B Read publication 2019 Epilepsy & Behavior 
Early Initiation of Long-Acting Injectable Antipsychotic Treatment is Associated with Lower Hospitalization Rates and Healthcare Costs in Patients with Schizophrenia: Real-World Evidence From US Claims Data Aripiprazole Munday J, Broder MS, Chang E, Hartry A, Yan TJ, Greene M
Read publication
2019 Current Medical Research & Opinion
Economic burden of relapse/recurrence in patients with major depressive disorder Vortioxetine Gauthier G, Mucha L, Shi S, Guerin A Read publication 2019 Journal of Drug Assessment
Effect of brexpiprazole on agitation and hostility in patients with acute schizophrenia Brexpiprazole  Citrome L, Ouyang J, Meehan SR, Baker RA, Weiss C Read publication 2019 Journal of Clinical Psychopharmacology
Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain Vortioxetine Yang K-C, Stepanov V, Amini N, Martinsson S, Takano A, Bundgaard C, Bang-Andersen B, Sanchez C, Halldin C, Farde L, Finnema SJ Read publication 2019 Neuropsychopharmacology
Effects of vortioxetine and escitalopram on electroencephalographic recordings – A randomized, crossover trial in healthy males Vortioxetine Nissen TD, Laursen B, Viardot G, l´Hostis P, Danjou P, Sluth LB, Gram M, Bastlund JF, Christensen SR, Drewes AM Read publication 2019 Neuroscience
Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis Vortioxetine Jacobson W, Harvey P, Zhong W, Nomikos G, Olsen CK, Christensen M Read publication 2019 Current Medical Research & Opinion
Efficacy and safety of brexpiprazole as adjunctive treatment in major depressive disorder: overview of four short-term studies Brexpiprazole  Thase M, Hobart M, Zhang P, Weiss C, Meehan SR Read publication 2019 Expert Opinion on Pharmacotherapy
Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials Brexpiprazole  Grossberg G, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, Slomkowski M, Baker RA, McQuade R, Cummings J Read publication 2019 American Journal of Geriatric Psychiatry
Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma Vortioxetine Christensen MC, Florea I, Loft H, McIntyre RS Read publication 2019 Journal of Affective Disorders
Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial Eptinezumab Dodick DW, Lipton RB, Silberstein S, Goadsby P4, Biondi D, Hirman J, Cady R, Smith J Read publication 2019 Cephalalgia
Exploration of treatment-resistant schizophrenia subtypes based on a survey of 204 US psychiatrists Lu AF35700 Correll CU, Brevig T, Brain C Read publication 2019 Neuropsychiatric Disease and Treatment
Health-related quality of life outcomes, economic burden and cost associated among diagnosed and undiagnosed depression patients in Japan Vortioxetine Yamabe K, Liebert R, Flores N Read publication 2019 ClinicoEconomics and Outcomes Research
Identifying and Characterizing Treatment-Resistant Schizophrenia in Observational Database Studies Lu AF35700 Jonsson L, Simonsen J, Brain C, Kymes S, Watson L Read publication 2019 International Journal of Methods in Psychiatric Research
Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: A 2-week, randomized, double-blind, placebo-controlled study Vortioxetine Vieta E, Florea I, Schmidt S N, Areberg J, Ettrup A Read publication 2019 International Clinical Psychopharmacology
Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder: results from the AtWoRC study Vortioxetine Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A Read publication 2019 CNS Spectrums
Management of Coexistent Neurogenic  Orthostatic Hypotension and Supine Hypertension Droxidopa Cannom D Read publication 2019 Journal of Clinical Hypertension
Management of Depression in Adolescents in Japan Escitalopram Saito T, Reines E, Florea I, Dalsgaard M Read publication 2019 Journal of Child and Adolescent Psychopharmacology
Medication adherence, health service use, and costs in patients with major depressive disorder initiating adjunctive antipsychotic treatment Brexpiprazole  Broder MS, Greene M, Yan T, Chang E, Hartry A, Yermilov I Read publication 2019 Clinical Therapeutics
Neurogenic Orthostatic Hypotension: A Nonmotor Symptom of Parkinson Disease Droxidopa Low P, Cutsforth-Gregory J Read publication 2019 Neurology and Therapy
Open-label, Multicenter, Phase 3 Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-moderate Alzheimer’s Disease Idalopirdine Frölich L, Alireza A, Ballard C, Tariot P, Molinuevo JL, Boneva N, Geist M, Raket L, Cummings J  Read publication 2019 Journal of Alzheimer's Disease
Parkinson Disease and Orthostatic Hypotension in the Elderly: Recognition and Management of Risk Factors for Falls Droxidopa LeWitt P, Kymes S, Hauser R Read publication 2019 Aging and Disease
Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial Vortioxetine Jacobsen P, Zhong W, Nomikos G, Clayton A Read publication 2019 The Journal of Sexual Medicine
Patient attitudes towards and goals for MDD treatment: A survey study Vortioxetine McNaughton E, Granskie J, Curran C, Opler M, Sarkey S, Mucha L, Eramo A, Francois C, Webber-Lind B, McCue M Read publication 2019 Patient Preference and Adherence
Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study Vortioxetine Haro JM, Hammer-Helmich L, Saragoussi D, Ettrup A, Larsen KG Read publication 2019 Neuropsychiatric Disease and Treatment
Pharmacokinetics and safety of vortioxetine in the Chinese population Vortioxetine Miao J, Wang G, Hou J, Areberg J, Zhao Y,  Højer AM, Ettrup A Read publication 2019 Advances in Therapy
Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide Eptinezumab Moldovan Loomis C, Dutzar B, Ojala EW, Hendrix L, Karasek C, Scalley-Kim M, Mulligan J, Fan P, Billgren J, Rubin V, Boshaw H, Kwon G, Marzolf S, Stewart E, Jurchen D, Pederson SM, Perrino McCulloch L, Baker B, Cady RK, Latham JA, Allison D, Garcia-Martinez LF Read publication 2019 Journal of Pharmacology and Experimental Therapeutics
Pharmacometrics of Clobazam in Pediatrics: Prediction of Effective Clobazam Doses for Dravet Syndrome Clobazam Tolbert D, Chu H-M, Ette EI Read publication 2019 Epilepsy Research
Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis Vortioxetine Liguori C, Ferini-Strambi L, Izzi F, Mari L, Manfredi N, D'Elia A, Mercuri NB, Placidi F Read publication 2019 British Journal of Clinical Pharmacology
Psychometric validation of Japanese version of Alcohol Quality of Life Scale (AQoLS) in the treatment of patients with alcohol use disorder – a non-interventional, prospective, longitudinal, multi-site cohort study Nalmefene Higuchi S, Moriguchi Y, Tan KHX Read publication 2019 Quality of Life Research
Real-life assessment of aripiprazole monthly (Abilify Maintena) in schizophrenia: a Canadian naturalistic non-interventional prospective cohort study Aripiprazole Mustafa S, Bougie J, Miguelez M, Clerzius G, Rampakakis E, Proulx J, Malla A Read publication 2019 BMC Psychiatry
Relationship of cognitive impairment with depressive symptoms and psychosocial function in patients with major depressive disorder: cross sectional analysis of baseline data from PERFORM-J Vortioxetine Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Tan K, Hammer-Helmich L, Fernandez J Read publication 2019 Journal of Affective Disorders
Results and validation of an index to measure health state of patients with depression in automated healthcare databases Vortioxetine Lamy FX, Falissard B, Francois C, Lancon C, Llorca PM, Tanaescu A, Touya M, Verpillat P, Wade A, Saragoussi D Read publication 2019 Journal of Market Access & Health Policy
Results of a Real-World Study of Vortioxetine in Patients with Major Depressive Disorder in South East Asia (REVIDA): Subgroup Analysis of Malaysian Patients Vortioxetine Chin CN, Azhar, Au YKC, Chong MSwee Woon, Yen TH, Yeoh BBD, Yap CH, Ku RKA, Keira JH Read publication 2019 Malaysian Journal of Psychiatry
Role of Nurses and Nurse Practitioners in the Recognition, Diagnosis, and Management of Neurogenic Orthostatic Hypotension Droxidopa Biswas D, Karabin B, Turner D Read publication 2019 International Journal of General Medicine
Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials. Vortioxetine Mahableshwarkar A, Jacobsen P, Affinito J, Reines E, Xu J, Nomikos G Read publication 2019 CNS Spectrums
Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies Aripiprazole Madera JJ, Such P, Zhao C, Baker RA Read publication 2019 Neuropsychiatric Disease and Treatment
The effect of aripiprazole once monthly on personal and social functioning: Post hoc analyses of acute and long-term studies Aripiprazole Peters-Strickland T, Baker RA, Such P, Zhang P, Madera JJ Read publication 2019 Neuropsychiatric Disease and Treatment
The patient perspective on cognitive symptoms in major depressive disorder: a retrospective database and prospective survey analysis Vortioxetine Chiauzzi E, Drahos J, Sarkey S, Curran C, Wang V, Tomori D Read publication 2019 Journal of Participatory Medicine
Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine Vortioxetine Nierenberg AA, Loft H, Olsen CK Read publication 2019 Journal of Affective Disorders
Treatment of Orthostatic Hypotension Due to Autonomic Dysfunction (Neurogenic Orthostatic Hypotension) in a Patient With Cardiovascular Disease and Parkinson Disease: A Case Report Droxidopa McCullough P Read publication 2019 Cardiology and Therapy
Treatment patterns and burden of behavioral disturbances in patients with dementia in the United States: a claims database analysis Brexpiprazole  Sanon Aigbogun M, Stellhorn R, Hartry A, Baker RA, Fillit H Read publication 2019 BMC Neurology
Use of Droxidopa for the Long-Term Treatment of Neurogenic Orthostatic Hypotension Droxidopa Hewitt LA, Raj S Read publication 2019 European Heart Journal
Use of the Functioning Assessment Short Test (FAST) in defining functional recovery in bipolar I disorder. Post-hoc analyses of long-term studies of aripiprazole once monthly as maintenance treatment Aripiprazole Madera JJ, Such P, Zhang P, Baker RA, Grande I Read publication 2019 Neuropsychiatric Disease and Treatment
Using self-reported vocational functioning measures to identify working patients with impaired functional capacity in major depressive disorder Vortioxetine Murthy V, Xu R, Zhong W, Harvey P Read publication 2019 Journal of Affective Disorders
Utility of Autonomic Testing for the Efficient Diagnosis and Effective Pharmacologic Management of Neurogenic Orthostatic Hypotension Droxidopa Suleman, A; Bin Alam, S; Almardini W Read publication 2019 BMJ Case Reports
Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized double-blind, placebo-controlled proof-of-concept study Vortioxetine Biederman J, Lindsten A, Sluth L B, Petersen M L, Ettrup A, Eriksen H-L F, Fava M Read publication 2019 Journal of Psychopharmacology
Wearable Technology for High-Frequency Cognitive and Mood Assessment in Major Depressive Disorder: Longitudinal Observational Study. Vortioxetine Cormack F, McCue M, Taptiklis N, Skirrow C, Glazer E, Panagopoulos E, van Schaik TA, Fehnert B, King J, Barnett JH Read publication 2019 JMIR Mental Health